© John Wiley & Sons Ltd
Edited By: Chim C. Lang, MD and Stuart D. Katz, MD
Impact Factor: 2.243
ISI Journal Citation Reports © Ranking: 2015: 60/124 (Cardiac & Cardiovascular Systems); 132/253 (Pharmacology & Pharmacy)
Online ISSN: 1755-5922
Thank you for your interest in Cardiovascular Therapeutics. Please read the complete Author Guidelines carefully prior to submission, including the section on copyright. To ensure fast peer review and publication, manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review.
Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at https://mc.manuscriptcentral.com/cdr
Full instructions and support are available on the site and a user ID and password can be obtained on the first visit. For technical support please dial +1 434 817 2040 ext. 167, or via the 'Get Help Now' link in the top right-hand corner of the login screen. If you cannot submit online, please contact the Editorial Office.
We look forward to your submission.
EDITORIAL AND CONTENT CONSIDERATIONS
Cardiovascular Therapeutics focuses on in-depth reviews and original articles on the pharmacology and pharmacokinetics, toxicology, human investigation and clinical trials of new or potential cardiovascular drugs. Articles in cardiovascular translational research, pharmacogenomics and personalized medicine, gene and cell therapies and pharmacoepidemiology are also encouraged.
Priority peer review service
EXPEDITED is the new author paid for rapid publication model from Cardiovascular Therapeutics helping you publish your clinical trials faster. The service is exclusively for well conducted, well reported clinical trials.
Priority peer review: 7 working days from online submission to first decision.
Priority proofs: 7 working days from 'accept' decision.
Priority publication: 7 working days from proof approval to Early View publication. Priority print: 'Late Breaker' publication in the next print issue. Exclusively for clinical trials (interventional and observational studies). Contact us for more information.
Step #1 - Apply to the Editorial Office >1 week before online submission with a detailed abstract, list of authors, contributorship statement, clinical trial registration details, clinical trial data posting details (if available), complete CONSORT or STROBE checklist (note: at this stage replace page numbers on this checklist with the word 'Yes' to confirm that each CONSORT/STROBE recommendation has been followed), details of research funding and disclosures of potential conflicts of interest.
Step #2 - We will confirm that we have received your application and whether we will expedite your peer review. If we accept your application for the EXPEDITED service, you will be required to sign an agreement acknowledging the terms and conditions before submission. You will receive an invoice for $1,500 which is non-refundable.
Step #3 - Submit online via the manuscript submission stub set up for you by the editorial office. Contact us for more information.
PREPARING YOUR SUBMISSION
You will be asked during online submission to confirm that your study has been approved by relevant bodies (e.g. institutional review boards, research ethics committees) and that appropriate consent was obtained for studies involving human participants.
The journal employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.
The journal is a member of, and subscribes to the principles of the Committee on Publication Ethics (COPE).
RANDOMIZED CLINICAL TRIALS should follow CONSORT guidelines; Templates for the checklist and flow chart can be downloaded from the CONSORT website. Per the requirements of the WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects (1964), amended by the 64th WMA GA, October 2013: Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject. Reports of clinical trials should include the clinical trial registration number and registry name at the end of the abstract.
DIAGNOSTIC studies should follow STARD guidelines;
META ANALYSIS should follow QUOROM guidelines;
EPIDEMIOLOGY studies should follow STROBE guidelines.
PARTICIPANT DATA should only be published with written informed consent.
Participants have a right to privacy that should not be infringed without informed consent. Masking the eye region in photographs of participants is an inadequate protection of anonymity and will result in the submission being rejected.
Photographs of participants should not be included unless the participant gives written informed consent for publication.
In online submission system, confirm that all listed authors meet ICMJE authorship criteria:
- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- Drafting the work or revising it critically for important intellectual content; AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be listed in the Acknowledgements section.
All Co-authors must be assigned to the submission within the submission system at step 3. Where editorial checks highlight authors missing, the submission will be returned to the corresponding author to correct this which will delay Editorial consideration.
Main document, including tables – MS word, rtf
Figures – EPS or high resolution TIFF
Please present your manuscript as follows. Note that errors and omissions and incomplete information will delay peer review and publication.
Word limits. The text ('Introduction' to the end of the author contributions) should not exceed 3,000 words, with a structured abstract of up to 250 words, and a maximum of 5 tables and/or figures total.
-Title and Running head (short title)
-Author byline: First name in full, middle initial (if any) and family name in full of all authors – no degree/ titles/ positions of responsibility.
Example: John Smith, Lydia Duncan, Giles Ramamorthy
-Affiliations: Number the affiliations and start each affiliation on a new line. Affiliations should include: department, institution, city and country for each unique affiliation
Link the affiliation to the author by adding the affiliation number to the author name in the author line.
Example: 1.Department of Cardiothoracic surgery, University of Bristol, Bristol, UK;
2.Pediatric Intensive Care Unit, Boston Children's Hospital, Boston, USA
- One corresponding author should be identified and their contact details written after the affiliations list as follows: Title(Mr/Mrs/Ms/Dr/Prof), first initial and family name. Example: Dr. J. E. Smith; add department, street, city, postal code, country. Email address;
-A structured abstract with subheadings for aim, method, results, and conclusion should be included before the main text;
-Six MeSH-compliant keywords should follow the abstract
- All submissions must have a clearly described aim after the Introduction.
-Disclosures: Indicate at the end of the text before references in this order:
Ethics - Any necessary ethical approval(s); PLEASE NOTE: Cohort studies require evidence of IRB approval: name of IRB, date of approval and approval code/reference number must be provided.
Funding - The source of funding for the study with grant numbers. Avoid negative statements. If no additional funding was received, state 'The study was funded by departmental resources.'
Disclosures - Any conflict of interest. Each author must disclose all financial relationships for the previous 12 months, whether or not they are related to the subject of the paper. If in doubt, disclose.
Author contributions - All authors listed must meet the ICMJE authorship criteria mentioned above (see ‘authorship’). Recommendation: Include a short description of each authors' contribution immediately before your references. (Examples of categories for authors' contributions: Concept/design, Data analysis/interpretation, Drafting article, Critical revision of article, Approval of article, Statistics, Funding secured by, Data collection.)
The American Medical Association (AMA) system of referencing should be used see the - AMA Manual of Style for details. All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order using Arabic superscript numerals. Sample references follow:
Diabetes mellitus is associated with a high risk of foot ulcers.1-3
Several interventions have been successful at increasing compliance.11,14-16
The data of Smith et al18 is further evidence of this effect.
As reported previously,1,3-6
The results were as follows4:
Journal article (1-6 authors):
1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. J Comp Neurol 1998;390:537-551.
Journal article with more than six authors:
2. Geller AC, Venna S, Prout M, et al. Should the skin cancer examination be taught in medical school? Arch Dermatol. 2002;138(9):1201-1203.
Journal article with no named author or group name:
3. Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use--Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59(9):273.
Online articles not yet published in an issue:
4. Smith JJ, Fihn SD, White RH. Treatment of allergic rhinitis. Am J Med. In press; doi:10.1016/S0002-9343(00)00545-3.
5. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.
6. Guyton JL, Crockarell JR. Fractures of acetabulum and pelvis. In: Canale ST, ed. Campbell's Operative Orthopaedics. 10th ed. Philadelphia, PA: Mosby, Inc; 2003:2939-2984.
7. Rudolph CD, Rudolph AM. Rudolph's Pediatrics. 21st ed. New York, NY: McGraw-Hill Companies; 2002. http://online.statref.com/Document/Document.aspx?DocID=1&StartDoc=1&EndDoc=1882&FxID=13&offset=7&SessionId=A3F279FQVVFXFSXQ. Accessed August 22, 2007.
8. American Cancer Society. Cancer Facts & Figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf. Accessed March 3, 2003. Please note that journal title abbreviations should conform to the practices of Chemical Abstracts.
Conference proceedings:  Irvin AD, Cunningham MP, Young AS, (2011) Advances in the control of Theileriosis. International Conference held at the International Laboratory for Research on Animal Diseases; 1981 Feb 9-13; Nairobi. Boston: Martinus Nijhoff Publishers;. 427 p.
Journal articles not yet in print:  Shi M, Gu H, Yin F, Zhu J, Yin X. (2015)Tissue Factor Pathway Inhibitor Coated Stents Inhibit Restenosis in a Rabbit Carotid Artery Model. Cardiovasc Ther. [Epub ahead of print] Published online 17 Aug 2015. doi: 10.1111/1755-5922.12152 Accessed 22 August 2015.
Webpage:  British Medical Journal/people [Internet]. Stanford, CA: Stanford Univ; 10 July 2014 Available from: http://bmj.bmjjournals.com [Accessed 31 August 2015]
Internet databases:  Askevold ET1, Gullestad L2, Nymo S3, Kjekshus J2, Yndestad A4, Latini R5, Cleland JG6, McMurray JJ7, Aukrust P8, Ueland T9 (2015) Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). PLoS One. 2015 Aug 19;10(8):e0133970. doi: 10.1371/journal.pone.0133970. eCollection 2015 [Accessed 31 August 2015]
-Tables should be numbered in the order in which they are mentioned in the text, and each should have a short explanatory caption. Each table column should have a short heading. Tables should appear at the end of your main document in tabulate text. Do not embed tables as pictures as these cannot be edited.
-Figure captions should be included in a list following the references/tables.
-Measurements should be given in the units in which they were made, but non-metric units must be accompanied by metric (SI) equivalents (exceptions: blood pressure in mmHg; haemoglobin in g/dl).
-Generic drug names should be used (drug brand names must not be used).
-Abbreviations should not be listed. The word should be written in full in the text and only followed by the abbreviation/ acronym in parentheses if the word is repeated three or more times subsequently. Example, anti-diuretic hormone (ADH).
-Latin letters in statistical values (eg t, p, n, N etc) should be presented in italics. This applies to the text, figures and tables
-The absolute P value should be reported (or P0.001). “P>0.05”, “P0.05” or “ns” are not acceptable.
All illustrations (line drawings and photographs) are classified as figures. Only those essential to the paper should be included. Figures should be numbered using Arabic numerals, and cited in consecutive order in the text. We are only able to use your original source files. Figures copied and pasted into word etc cannot be used by the publisher. Each figure should be supplied as a separate file, with the figure number incorporated in the file name. The accepted file types are: EPS (preferred format for line work) or high resolution TIFF (at least 300 dpi at finished size). Figures should not be smaller than 85mm wide (single column figure) or 180mm wide (full page figure) at 300dpi. Please do not submit higher than 600 dpi figures as this results in large file sizes which can make review difficult.
Permission to include published material
Permission to reproduce material within the manuscript must be obtained in advance by the corresponding author. Refer to the organization responsible for managing the rights of the original author. Expect this to take up to six weeks. Once granted, upload a copy of the approval as a supporting file. Full attribution to the source must be made in the figure caption.
Supporting information is not essential to the article but provides greater depth and background and may include tables, figures, videos, datasets, etc. This material can be submitted as a separate file at the time of submission, and will appear online, without editing or typesetting. Guidelines on how to prepare this material and which formats and files sizes are acceptable can be found at: http://authorservices.wiley.com/bauthor/suppmat.asp.
Please note that the provision of supporting information is not encouraged as a general rule. It will be assessed critically by reviewers and editors and will only be accepted if it is essential.
Submissions are not accepted via email. Please submit your final files online at https://mc.manuscriptcentral.com/cdr Some reminders:
- At submission step 3 – please add all co-authors
- At submission step 5 – please include a cover letter – this should be typed directly into the box provided and should include the following: (i) an explanation about why your manuscript is suitable; and (ii) an indication of whether the research has been published before as an abstract, presented at a scientific meeting, or published in a clinical trial data posting. Note this will not jeopardize full peer reviewed publication in the journal).
- At submission step 6 – please upload your main document containing all text elements and the tables (if any) in MS word, and then any figures, supplementary material and permissions clearance statements (if any) as separate files
PUBLICATION PROCESS AFTER ACCEPTANCE
Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper. More details on the copyright and licencing options for the journal appear below.
Wiley’s Author Services
Author Services enables authors to track their article through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The corresponding author will receive a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Visit http://www.authorservices.wiley.com/ for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.
The journal offers Wiley’s Accepted Articles service for all manuscripts. This service ensures that accepted ‘in press’ manuscripts are published online very soon after acceptance, prior to copy-editing or typesetting. Accepted Articles are published online a few days after final acceptance, appear in PDF format only, are given a Digital Object Identifier (DOI), which allows them to be cited and tracked, and are indexed by PubMed. After print publication, the DOI remains valid and can continue to be used to cite and access the article. The Accepted Articles service has been designed to ensure the earliest possible circulation of research papers after acceptance. Given that copyright licensing is a condition of publication, a completed copyright form is required before a manuscript can be processed as an Accepted Article. Accepted articles will be indexed by PubMed; therefore the submitting author must carefully check the names and affiliations of all authors provided in the cover page of the manuscript, as it will not be possible to alter these once a paper is made available online in Accepted Article format. Subsequently the final copyedited and proofed articles will appear in an issue on Wiley Online Library; the link to the article in PubMed will automatically be updated.
Once the paper has been typeset the corresponding author will receive an e-mail alert containing instructions on how to provide proof corrections to the article. It is therefore essential that a working e-mail address is provided for the corresponding author. Proofs should be corrected carefully; the responsibility for detecting errors lies with the author. The proof should be checked, and approval to publish the article should be emailed to the Publisher by the date indicated; otherwise, it may be signed off on by the Editor or held over to the next issue.
The journal offers rapid speed to publication via Wiley’s Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. Early View articles are given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before allocation to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article.
A PDF reprint of the article will be supplied free of charge to the corresponding author. Additional printed offprints may be ordered online for a fee. Please click on the following link and fill in the necessary details and ensure that you type information in all of the required fields: http://offprint.cosprinters.com/cos. If you have queries about offprints please e-mail: firstname.lastname@example.org.
Author Marketing Toolkit
The Wiley Author Marketing Toolkit provide authors with support on how to use social media, publicity, conferences, multimedia, email and the web to promote their article.
COPYRIGHT, LICENSING AND ONLINE OPEN
Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper.
Authors may choose to publish under the terms of the journal’s standard copyright transfer agreement (CTA), or under open access terms made available via Wiley OnlineOpen.
Standard Copyright Transfer Agreement: FAQs about the terms and conditions of the standard CTA in place for the journal, including standard terms regarding archiving of the accepted version of the paper, are available at: Copyright Terms and Conditions FAQs.
Note that in signing the journal’s licence agreement authors agree that consent to reproduce figures from another source has been obtained.
OnlineOpen – Wiley’s Open Access Option: OnlineOpen is available to authors of articles who wish to make their article freely available to all on Wiley Online Library under a Creative Commons license. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made open access. Authors of OnlineOpen articles are permitted to post the final, published PDF of their article on their personal website, and in an institutional repository or other free public server immediately after publication. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.
OnlineOpen licenses. Authors choosing OnlineOpen retain copyright in their article and have a choice of publishing under the following Creative Commons License terms: Creative Commons Attribution License (CC BY); Creative Commons Attribution Non-Commercial License (CC BY NC); Creative Commons Attribution Non-Commercial-NoDerivs License (CC BY NC ND). To preview the terms and conditions of these open access agreements please visit the Copyright Terms and Conditions FAQs.
Funder Open Access and Self-Archiving Compliance: Please click here for more information on Wiley’s compliance with specific Funder Open Access and Self Archiving Policies, and click here for more detailed information specifically about Self-Archiving definitions and policies.
Cardiovascular Therapeutics is published in electronic format only.
Author Guidelines updated 22 August 2015